Smith & Nephew PLC header image

Smith & Nephew PLC

SNN

Equity

ISIN null / Valor 1111046

CTA NASDAQ OMX Stock Exchange (2026-09-04)
USD 28.87+0.63%

Smith & Nephew PLC
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Smith & Nephew PLC is a global medical technology company that develops and manufactures a wide range of clinical devices and solutions for orthopaedics, advanced wound management, sports medicine, and ear, nose, and throat (ENT) procedures. The company’s orthopaedics division produces implants for hip and knee joint replacements, along with trauma products designed to stabilize fractures and correct bone deformities, while also incorporating robotics-assisted technologies to support surgical precision. Its advanced wound management offerings cover a variety of products for treating both acute and chronic wounds, including conditions such as diabetic and pressure ulcers, burns, and post-operative complications. In addition, the sports medicine and ENT portfolios provide instruments and implants for minimally invasive soft tissue repairs and various ENT procedures. Overall, Smith & Nephew leverages these diversified capabilities to address a broad spectrum of clinical needs within the healthcare sector.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-23.3%1Y
7.44%3Y
-25.5%5Y

Performance

28.1%1Y
65.2%3Y
53.3%5Y

Volatility

Market cap

12266 M

Market cap (USD)

Daily traded volume (Shares)

851,038

Daily traded volume (Shares)

1 day high/low

24.76 / 24.55

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Viatris Inc
Viatris Inc Viatris Inc Valor: 58198423
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%USD 16.88
Oncopeptides AB
Oncopeptides AB Oncopeptides AB Valor: 35671972
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.77%SEK 1.78
Roivant Sciences Limited
Roivant Sciences Limited Roivant Sciences Limited Valor: 113331044
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.51%USD 34.93
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.25%USD 28.45
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.18%USD 70.25
Galderma Group Ltd
Galderma Group Ltd Galderma Group Ltd Valor: 133539272
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.17%CHF 158.38
Surgery Partners Inc
Surgery Partners Inc Surgery Partners Inc Valor: 29308003
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.64%USD 14.26
AstraZeneca PLC
AstraZeneca PLC AstraZeneca PLC Valor: 982352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.15%GBP 120.06
LivaNova PLC
LivaNova PLC LivaNova PLC Valor: 28726218
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.89%USD 81.92
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1103058
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.14%GBP 10.64